Concert Pharmaceuticals (CNCE) Receives Hold Rating from Mizuho

Mizuho reaffirmed their hold rating on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a research note published on Tuesday morning. They currently have a $23.00 price objective on the biotechnology company’s stock.

CNCE has been the topic of several other reports. BidaskClub upgraded Concert Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Saturday, December 9th. Zacks Investment Research upgraded Concert Pharmaceuticals from a sell rating to a hold rating in a research note on Monday. TheStreet upgraded Concert Pharmaceuticals from a c+ rating to a b- rating in a research note on Monday, January 8th. HC Wainwright restated a buy rating and issued a $21.00 target price on shares of Concert Pharmaceuticals in a research note on Friday, October 20th. Finally, UBS Group set a $34.00 target price on Concert Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, December 19th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Concert Pharmaceuticals has a consensus rating of Buy and an average price target of $24.33.

Shares of Concert Pharmaceuticals (NASDAQ:CNCE) opened at $20.26 on Tuesday. Concert Pharmaceuticals has a one year low of $9.01 and a one year high of $30.71.

In related news, Director Richard Aldrich sold 31,236 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $19.14, for a total transaction of $597,857.04. Following the sale, the director now directly owns 286,975 shares in the company, valued at approximately $5,492,701.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronald W. Barrett sold 14,156 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $24.70, for a total value of $349,653.20. Following the sale, the director now owns 3,539 shares in the company, valued at $87,413.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,433,248 shares of company stock worth $37,226,329. Corporate insiders own 10.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in CNCE. BlackRock Inc. raised its stake in shares of Concert Pharmaceuticals by 57.2% during the 4th quarter. BlackRock Inc. now owns 1,786,223 shares of the biotechnology company’s stock valued at $46,210,000 after purchasing an additional 649,808 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Concert Pharmaceuticals during the 4th quarter valued at $7,713,000. Bogle Investment Management L P DE bought a new stake in shares of Concert Pharmaceuticals during the 4th quarter valued at $7,554,000. Senvest Management LLC raised its stake in shares of Concert Pharmaceuticals by 458.8% during the 3rd quarter. Senvest Management LLC now owns 314,629 shares of the biotechnology company’s stock valued at $4,641,000 after purchasing an additional 258,329 shares during the period. Finally, Ingalls & Snyder LLC raised its stake in shares of Concert Pharmaceuticals by 14.5% during the 3rd quarter. Ingalls & Snyder LLC now owns 1,209,062 shares of the biotechnology company’s stock valued at $17,834,000 after purchasing an additional 153,062 shares during the period. Institutional investors own 67.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Concert Pharmaceuticals (CNCE) Receives Hold Rating from Mizuho” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://stocknewstimes.com/2018/02/14/concert-pharmaceuticals-cnce-receives-hold-rating-from-mizuho.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply